Clinical trials: Muscle Spasticity
Spasticity Due to Cerebral Palsy
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild…
- Trial name
- NCT01405950
- Testing
- Zanaflex Capsules
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Acorda Therapeutics
Spastic Cerebral Palsy
Short Term Follow-up of a Botulinum Toxin Intervention in Children With Spastic Cerebral Palsy
This study investigates the effect of integrated Botulinum Neurotoxin A (BoNT) treatment on morphologic muscle and tendon properties, spasticity, joint stiffness, joint range of motion, muscle strength, gait and gross motor…
- Trial name
- NCT05126693
- Testing
- Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.
- Where
- Belgium
- Volunteers
- 61 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cerebral Palsy Spastic Diplegia
Cerebral Palsy: Short-burst Interval Training
This study examines the effect of short burst interval treadmill training in ambulatory children with cerebral palsy. Half the sample will receive 20 sessions of training over 4 weeks, while half will receive the training over 10…
- Trial name
- NCT03373890
- Testing
- Short Burst Interval Locomotor Treadmill Training (SBLTT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Seattle Children's Hospital
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cerebral Palsy, Muscle Spasticity
Effect of Botox and Vibration on Bone in Children With Cerebral Palsy
Cerebral palsy (CP) is a neuromuscular disorder that affects approximately 800,000 individuals in the U.S. An estimated 70-80% of these individuals have spasticity which affects ambulation and requires management.
- Trial name
- NCT01803464
- Testing
- Low-magnitude vibration, Botox
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).
- Trial name
- PUL (NCT02106351)
- Testing
- Botulinum toxin type A
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 212 people
- Sponsor
- Ipsen
Cerebral Palsy, Muscle Spasticity
Dysport® Pediatric Lower Limb Spasticity Study
The purpose of this research study is to determine whether Dysport® is effective in the treatment of increased stiffness of the calf muscles and to evaluate the safety of this treatment in children with Cerebral Palsy.
- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Trial name
- NCT01249417
- Testing
- Botulinum toxin type A
- Where
- 29 sites in United States, Chile and 4 more
- Volunteers
- 241 people
- Sponsor
- Ipsen
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan
Cerebral Palsy
Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in children with spastic diplegia cerebral palsy.
- Trial name
- NCT03469999
- Testing
- Dysport Injectable Product
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603615
- Testing
- Botulinum Toxin Type A
- Where
- 48 sites in United States, Canada and 7 more
- Volunteers
- 220 people
- Sponsor
- Allergan
Cerebral Palsy, Muscle Spasticity
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
The purpose of this research study was to determine the long term safety and efficacy of repeated treatments with Dysport® used in the treatment of lower limb spasticity in children with dynamic equinus foot deformity due to…
- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Trial name
- NCT01251380
- Testing
- Botulinum toxin type A
- Where
- 27 sites in United States, Chile and 4 more
- Volunteers
- 216 people
- Sponsor
- Ipsen
Stroke, Brain Injuries
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
- Conditions
- Stroke, Brain Injuries, Spasticity
- Trial name
- NCT00178646
- Testing
- Botox
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Lower Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy
- Trial name
- NCT01603628
- Testing
- botulinum toxin Type A
- Where
- 53 sites in United States, Hungary and 7 more
- Volunteers
- 384 people
- Sponsor
- Allergan
Sjögren-Larsson Syndrome
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered…
- Trial name
- NCT02402309
- Testing
- Active topical NS2 1% dermatologic cream
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cerebral Palsy, Spastic
Progressive Supervised Home-based Strength Training in Children With Spastic Cerebral Palsy
A randomized controlled trail will be carried out to investigate the effect of a 12-week supervised home-based progressive strength intervention in children with spastic cerebral palsy aged 5-11 years.
- Trial name
- NCT03863197
- Testing
- Progressive strength training
- Where
- 2 sites in Belgium
- Volunteers
- 49 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cerebral Palsy
Short-Burst Interval Treadmill Training Cerebral Palsy
Ambulatory children with cerebral palsy (CP) walk predominately in low intensity stride rates with little variability, thus limiting their walking activity and ability to participate in daily life.
- Trial name
- NCT04026295
- Testing
- Short Burst Interval Treadmill Training (SBLTT), Traditional Locomotor Treadmill Training (TLTT)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Kristie Bjornson
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle…
- Trial name
- NCT01905683
- Testing
- IncobotulinumtoxinA (16-20 Units per kg body weight)
- Where
- 43 sites in Austria, Czechia and 10 more
- Volunteers
- 370 people
- Sponsor
- Merz Pharmaceuticals GmbH
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy
- Trial name
- NCT01603641
- Testing
- Botulinum Toxin Type A
- Where
- 56 sites in United States, Hungary and 7 more
- Volunteers
- 370 people
- Sponsor
- Allergan
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan